Landscape Capital Management L.L.C. Purchases Shares of 73,819 Boston Scientific Co. (NYSE:BSX)
Landscape Capital Management L.L.C. purchased a new stake in Boston Scientific Co. (NYSE:BSX) during the 2nd quarter, Holdings Channel reports. The fund purchased 73,819 shares of the medical equipment provider’s stock, valued at approximately $3,173,000.
Several other institutional investors and hedge funds have also recently made changes to their positions in BSX. Marshall Wace LLP lifted its stake in shares of Boston Scientific by 251.5% during the first quarter. Marshall Wace LLP now owns 4,413,791 shares of the medical equipment provider’s stock valued at $169,401,000 after buying an additional 3,158,088 shares during the period. Marshall Wace North America L.P. lifted its stake in shares of Boston Scientific by 38.3% during the first quarter. Marshall Wace North America L.P. now owns 9,002,670 shares of the medical equipment provider’s stock valued at $345,522,000 after buying an additional 2,494,598 shares during the period. Geode Capital Management LLC lifted its stake in shares of Boston Scientific by 11.3% during the fourth quarter. Geode Capital Management LLC now owns 16,982,002 shares of the medical equipment provider’s stock valued at $599,030,000 after buying an additional 1,724,046 shares during the period. Ownership Capital B.V. purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $53,179,000. Finally, Janus Henderson Group PLC lifted its stake in shares of Boston Scientific by 3.1% during the second quarter. Janus Henderson Group PLC now owns 39,252,231 shares of the medical equipment provider’s stock valued at $1,687,034,000 after buying an additional 1,162,625 shares during the period. 90.60% of the stock is currently owned by institutional investors and hedge funds.
In other news, EVP Joseph Michael Fitzgerald sold 20,673 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $43.41, for a total value of $897,414.93. Following the completion of the sale, the executive vice president now owns 226,835 shares of the company’s stock, valued at $9,846,907.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David A. Pierce sold 5,140 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $38.45, for a total transaction of $197,633.00. Following the completion of the sale, the executive vice president now directly owns 27,173 shares of the company’s stock, valued at approximately $1,044,801.85. The disclosure for this sale can be found here. Insiders sold 63,289 shares of company stock valued at $2,611,790 in the last three months. Company insiders own 0.66% of the company’s stock.
BSX stock traded up $0.64 on Thursday, hitting $42.07. 179,158 shares of the company were exchanged, compared to its average volume of 5,758,131. Boston Scientific Co. has a twelve month low of $31.56 and a twelve month high of $43.66. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.31 and a quick ratio of 1.04. The company has a fifty day simple moving average of $42.52. The firm has a market cap of $57.65 billion, a PE ratio of 28.59, a price-to-earnings-growth ratio of 2.54 and a beta of 0.80.
Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.01. Boston Scientific had a net margin of 13.85% and a return on equity of 23.29%. The company had revenue of $2.63 billion during the quarter, compared to analyst estimates of $2.64 billion. During the same quarter in the prior year, the business earned $0.41 earnings per share. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. Sell-side analysts predict that Boston Scientific Co. will post 1.56 earnings per share for the current year.
Boston Scientific Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.
Further Reading: Depreciation
Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.